Laboratory Products
New Tool to Aid the Detection of Alpha-1,3-Gal Glycans in Biopharmaceuticals
Feb 11 2011
Adding to their range of glycan standards products, Ludger Ltd now offer a 2-AB labelled alpha-1,3-Gal standard. This glycan standard can be used during glycoprofiling as a positive control for sequencing experiments utilising alpha1-3 galactose specific exoglycosidase.
The presence of Gal alpha-1-3-Gal structures within biopharmaceuticals is of huge importance to the pharmaceutical industry. Gal alpha 1-3 Gal (also known as Alpha Gal) is a potentially immunogenic glycan, which has been reported to be present in recombinant biological pharmaceuticals. It is found in the meat of non-primate mammals, cows milk and dog and cat dander. Humans cannot synthesize the glycan but can express antibodies against this structure. Anti-Gal antibodies comprise 1% of circulating IgG antibodies in all humans. An IgE-mediated allergic/hypersensitivity response to this glycan was observed in patients taking Cetuximab as a cancr treatment. Cetuximab is a chimeric murine-human cell monoclonal antibody. The cause for developing IgE antibodies specific to Alpha-Gal has been reported to occur after being bitten by certain types of tick; cases have been concentrated predominantly in the Southeast United States and parts of Australia.
In humans the production of anti-Gal antibodies has presented a unique opportunity for developing methods that harness the immunologic potential of this antibody for clinically beneficial outcomes. Anti-Gal IgG molecules bound to -gal epitopes on particulate or soluble vaccines will target them to APC at the vaccination site, and induce effective uptake of the vaccine by APC.
Digital Edition
Lab Asia 31.6 Dec 2024
December 2024
Chromatography Articles - Sustainable chromatography: Embracing software for greener methods Mass Spectrometry & Spectroscopy Articles - Solving industry challenges for phosphorus containi...
View all digital editions
Events
Nov 27 2024 Istanbul, Turkey
Jan 22 2025 Tokyo, Japan
Jan 22 2025 Birmingham, UK
Jan 25 2025 San Diego, CA, USA
Jan 27 2025 Dubai, UAE